Generated by AI
Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for cancer treatment. The company’s current pipeline centers on targeted medicines and immuno-oncology approaches designed to address molecular drivers of disease and support use alongside other treatment options. Its lead programs include vebreltinib, an oral c-Met inhibitor being studied in solid tumors with MET dysregulation, and APL-102, an oral multi-kinase inhibitor in early-stage cancer development. Apollomics also evaluates therapies for difficult-to-treat cancers such as non-small cell lung cancer and acute myeloid leukemia. Based in Foster City, California, Apollomics operates as a specialized biotechnology company within the broader oncology drug-development market, where it contributes experimental therapies aimed at precision medicine and unmet medical needs.
Website989 East Hillsdale Blvd.
Foster City, CA, 94404
United States
The latest articles about APLM.
Summary of Dec 29's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Summary of Dec 29's posts. Generated by AI.
Investors talking about APLM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.